Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
Public ClinicalTrials.gov record NCT00099255. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma, Large Cell Transformation of Mycosis Fungoides, and Lymphomatoid Papulosis
Study identification
- NCT ID
- NCT00099255
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Seagen Inc.
- Industry
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Interventions
- SGN-30 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2004
- Primary completion
- Jan 31, 2007
- Completion
- Jan 31, 2007
- Last update posted
- Dec 17, 2014
2004 – 2007
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| University of California at Los Angeles | Los Angeles | California | 90095 | — |
| Stanford University | Stanford | California | 94305 | — |
| Yale | New Haven | Connecticut | 06520 | — |
| Northwestern Universtiy | Chicago | Illinois | 60611 | — |
| University of Illinois at Chicago | Chicago | Illinois | 60612 | — |
| Johns Hopkins | Baltimore | Maryland | 21827 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Memorial Sloan-Kettering | New York | New York | 10021 | — |
| Cleveland University | Cleveland | Ohio | 44106 | — |
| Kaiser Permanente - Oncology Research | Portland | Oregon | 97227 | — |
| Vanderbilt University | Nashville | Tennessee | 37232 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00099255, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 17, 2014 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00099255 live on ClinicalTrials.gov.